Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer Tateaki Naito, MD, PhD, Fumihiro Tanaka, MD, PhD, Akira Ono, MD,

Slides:

Advertisements

Similar presentations

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB Martin J. Edelman, MD, Lydia.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer Wolf Köster, MD, Andrea Heider, MD, Norbert.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis Annemarie T. Fernandes, BA, Eric.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma Isabelle Opitz, MD, Martina Friess,

A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors Tomohide Tamura, MD, Hironobu Minami, MD, Yasuhide Yamada,

The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer Hirotsugu Kenmotsu, MD, Tateaki Naito, MD, Madoka.

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Can Determination of Circulating Endothelial Cells and Serum Caspase-Cleaved CK18 Predict for Response and Survival in Patients with Advanced Non–Small-Cell.

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

John E. Pilling, FRCS (CTh), Michael E

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) Primo N. Lara,

Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third- Line Chemotherapy for Small Cell Lung Cancer Satoshi Igawa, MD, PhD,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion

Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study Seiji Niho,

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Disease Control as a Predictor of Survival with Gefitinib and Docetaxel in a Phase III Study (V-15-32) in Advanced Non-small Cell Lung Cancer Patients

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer Mohammad Chakra, MD, Jean Louis Pujol,

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

Are discordant positron emission tomography and pathological assessments of the mediastinum in non–small cell lung cancer significant? Daniel J. Tandberg,

Clinical Relevance of Our Multimodality Prognostic Score

It’s All in the “Swerve of the Curve”

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Pulmonary Resection for Metastases from Colorectal Cancer

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

S-1 Treatment for Chemorefractory Thymic Carcinoma

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features Min-Woong Kang, MD, PhD, Eung-Sirk.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Thymic Small Cell Carcinoma Shows Marked Response to Amrubicin

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed “Sensitive” Small Cell Lung Cancer Anita Schwandt, MD, Tarek.

Presentation transcript:

Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer Tateaki Naito, MD, PhD, Fumihiro Tanaka, MD, PhD, Akira Ono, MD, Kazue Yoneda, BS, Toshiaki Takahashi, MD, PhD, Haruyasu Murakami, MD, PhD, Yukiko Nakamura, MD, Asuka Tsuya, MD, PhD, Hirotsugu Kenmotsu, MD, Takehito Shukuya, MD, Kyoichi Kaira, MD, PhD, Yasuhiro Koh, MD, Masahiro Endo, MD, PhD, Seiki Hasegawa, MD, PhD, Nobuyuki Yamamoto, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 3, Pages 512-519 (March 2012) DOI: 10.1097/JTO.0b013e31823f125d Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Box plots were drawn using the minimum and maximum values and the 25th, 50th, and 75th percentiles. A, Circulating tumor cell (CTC) levels at the baseline and the disease stage. ED, extensive disease; LD, limited disease. B, CTC levels at the baseline and number of metastatic organs. C, CTC levels at the baseline and the timing of blood sampling. p values calculated by Wilcoxon's test and analysis of variance (ANOVA) are presented. Journal of Thoracic Oncology 2012 7, 512-519DOI: (10.1097/JTO.0b013e31823f125d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan-Meier curves for overall survival in patients with <8 and ≥8 circulating tumor cells (CTCs) at the baseline in the full set of data (A), extensive disease subset (B), and limited disease subset (C). Kaplan-Meier curves for posttreatment survival and postrelapse survival in patients with <8 and ≥8 CTCs posttreatment and at relapse (D and E). p values calculated by the log-rank test are presented. Journal of Thoracic Oncology 2012 7, 512-519DOI: (10.1097/JTO.0b013e31823f125d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Kaplan-Meier curves for posttreatment survival in three groups, including patients in whom the baseline and posttreatment circulating tumor cell (CTC) levels remained at <8 (group A), patients in whom the CTC level converted from ≥8 to <8 cells (group B), and patients in whom the posttreatment CTC level was ≥8 cells (group C). p values calculated by the log-rank test are presented. Journal of Thoracic Oncology 2012 7, 512-519DOI: (10.1097/JTO.0b013e31823f125d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Receiver operator characteristics curve analysis for predicting 1-year survivors. The area under the curve is 0.70 (95% confidence interval [CI], 0.52–0.83) for the circulating tumor cell (CTC) level at baseline, 0.67 (95% CI 0.49–0.82) for serum lactate dehydrogenese (LDH) at baseline, 0.68 (95% CI 0.52–0.82) for serum neuron-specific enolase (NSE) at baseline, and 0.46 (95% CI 0.29–0.64) for serum progastrin-releasing peptide (ProGRP) at baseline. Journal of Thoracic Oncology 2012 7, 512-519DOI: (10.1097/JTO.0b013e31823f125d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 5 Relationship between radiologic response and the changes in the circulating tumor cell (CTC) level. A, Baseline and posttreatment CTC levels in patients showing PD (solid line) and SD (dotted line). B, Baseline and posttreatment CTC levels in patients showing PR (solid line) and CR (dotted line). PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response. Journal of Thoracic Oncology 2012 7, 512-519DOI: (10.1097/JTO.0b013e31823f125d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions